New price-cap agreement on hospital medicine in Denmark signed

20 December 2012

In accordance with the decision taken at the Danish Association of the Pharmaceutical Industry (Lif) budget meeting on December 13, 2012, the Ministry of Health and Prevention, the Danish Regions and the Lif have now signed a new price-cap and price reduction agreement for hospital medicine.

Under this present agreement on price reductions and a price-cap for prices for hospital-only medicines in Denmark in the period between January 1, 2013 and December 31, 2015, the Lif, the Ministry of Health and Prevention and the Danish Regions have extended and reduced the price-caps set out in the agreement of June 2009.

The agreement means that Lif, the Ministry of Health and Prevention and the Danish Regions have continued responsible, agreed solutions for the pharmaceutical industry in Denmark that will ensure predictability and a balance between the interests of the patients and the parties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >